478 results about "Dry eyes" patented technology

The invention relates to the technical field of artificial intelligence, and discloses a traditional Chinese medicine diabetes dry eye treatment difference evaluation system and method based on artificial intelligence, and the system comprises a four-diagnosis integrated module, a syndrome modeling module, an intelligent decision module, a curative effect feedback module, a knowledge base management module and a self-adaptive learning module. Multi-mode traditional Chinese medicine four-diagnosis data of tongue condition, pulse condition and eye diagnosis and modern physiological parameters of metabolic indexes are fused, a deep learning method is adopted for standardization processing, the problem that traditional Chinese medicine syndrome differentiation depends on subjective experience is solved, traditional Chinese medicine syndrome feature extraction of diabetes dry eye has objectivity and quantifiability, and the traditional Chinese medicine syndrome feature extraction efficiency is improved. The comprehensiveness and the accuracy of the diagnosis basis are improved; and the curative effect feedback module compares a prediction result with revival curative effect data in real time, and the knowledge base management module is linked to carry out case feature matching and strategy optimization, so that continuous optimization and long-term reliability of the treatment decision model are ensured.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

A dry eye composition containing hypochlorous acid and a demulcent. The demulcent can be polyvinylpyrrolidoe with a molecular weight of 30-50 kDa. The composition can be applied to the surface of the eye with a dropper device or a spray dispenser. Critically, hypochlorous acid is stable in the dry eye composition and maintains its effectiveness at preventing microbial growth.

The utility model relates to the technical field of contact lenses, and particularly discloses a comfortable sclera lens which comprises an outer surface, the inner side of the outer surface is connected with an optical area, the periphery of the optical area is sequentially provided with a first transition area, a second transition area and a landing area, the first transition area and the second transition area are connected with each other, and the optical area is not in contact with the cornea. A plurality of liquid guide grooves are evenly formed in the inner side of the landing area at intervals, the inner ends of the liquid guide grooves penetrate through the first transition area and the second transition area and extend to the edge of the optical area, through holes are formed in the positions, close to the edge of the landing area, of the bottoms of the liquid guide grooves, and the through holes penetrate through the landing area. According to the sclera lens, the plurality of liquid guide grooves are formed, tear exchange between the sclera lens and the periphery of the eyes can be achieved after the sclera lens is worn, the situation that the eyes are dry after the sclera lens is worn for a long time is relieved, meanwhile, the through holes are formed in the inner sides of the liquid guide grooves, the tear exchange efficiency can be further improved through the through holes, the oxygen permeation rate can be improved, and the comfort degree is high when the sclera lens is worn.

The invention discloses an image processing system and method for distinguishing xerophthalmia types, and relates to the technical field of image processing, and the method comprises the steps: firstly carrying out the standardization preprocessing of an original infrared meibomian gland image, further introducing an artifact perception link, and actively recognizing and positioning the interference regions, such as eyelash shielding and uneven illumination, in the image; and guiding the subsequent meibomian gland segmentation process by using the sensed artifact information, thereby realizing the accurate extraction of the meibomian gland form under the complex background. On the basis, multi-dimensional quantification is carried out on the precisely segmented gland form, and image features are converted into objective numerical indexes. And finally, carrying out comprehensive judgment on the numerical indexes by utilizing a decision tree model, and outputting standardized MGD severity grade. In this way, interference information brought by image artifacts can be intelligently suppressed, and therefore more robust and accurate MGD severity grading is achieved in a clinical image with poor quality.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention discloses a dry eye disease course supervision and prediction method and system based on AI image recognition, and relates to the technical field of medical image processing, and the method comprises the steps: obtaining blink behavior video data, meibomian gland infrared imaging data and time sequence ocular surface microvessel image data; analyzing the blink behavior video data, and extracting blink feature data; performing image processing on the infrared imaging data of the meibomian glands, and extracting feature data of the meibomian glands; carrying out binarization and thinning processing on the sequential ocular surface microvascular image data, and extracting blood vessel feature data; standardizing the blood vessel feature data, and fusing to generate a comprehensive feature vector; inputting the comprehensive feature vector into a classification model, and judging a dry eye disease course stage; executing trend analysis based on historical data of the comprehensive feature vector, and generating prediction data and intervention suggestion data; the method has the beneficial effects that through multi-modal image data fusion analysis, accurate monitoring and prediction of the xerophthalmia course are realized, and a scientific basis is provided for clinical intervention.

The present invention relates generally to compositions, formulations, and methods for immunotherapy and drug delivery, including the treatment of eye diseases such as dry eye disease (DED). In particular, the present invention relates to methods of producing exosomes from mesenchymal stem cells (MSC-Exos) and, optionally, loading said exosomes with one or more bioactive substances. The exosomes may be loaded using electroporation with one or more bioactive substances such as proteins, miRNAs, and / or siRNA. In specific embodiments, the exosomes, and / or one or more biological compounds derived from the exosomes, may be provided to an individual in need thereof, including as part of one or more compositions containing mesenchymal stem cells (MSCs). The individual in need thereof may be an individual having a medical disorder such as DED, immune disorders, cancer, and other disorders. Therefore, the compositions containing MSCs can be used for topical application to the eye. The compositions can contain MSCs, MSC-Exos, one or more MSC-derived biological compounds (e.g., growth factors, proteins, etc.).

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

In one aspect, a computerized method includes the step of obtaining a set of eye data of a patient from a medical practitioner in a computer input form. The method includes the step of acquiring a set of dry eye patient data from a set of well-structured dry eye patient data samples, wherein each sample dry eye patient data comprises a plurality of features. The method includes the step of identifying the plurality of data features in the set of well-structured dry eye patient data samples. The method includes the step of implementing a data cleaning process on the set of well-structured dry eye patient data samples. The method includes the step of implementing a feature selection on the set of well-structured dry eye patient data samples, wherein the feature selection comprises selecting a subset of relevant features for machine-learning model construction. The method includes the step of providing a specified machine-learning (ML) model. The method includes the step of training the ML model with the set of well-structured dry eye patient data samples. The method includes the step of validating the ML model with the set of well-structured dry eye patient data samples. The method includes the step of providing the set of eye data of the patient to the trained and validated ML model. With the trained and validated ML model, the method includes the step of classifying the set of eye data of the patient as a dry eye category and a dry eye type.

According to the xerophthalmia core index multi-task AI detection system, method and terminal provided by the invention, the xerophthalmia multi-modal image is collected and exclusive preprocessing is completed, and core index detection is carried out on the preprocessed image based on the xerophthalmia multi-index detection model, so that the xerophthalmia core index detection result is obtained. Outputting detection results such as meibomian gland deletion rate, tear film rupture time, staining classification, tear river height and blepharitis marginal inflammation classification; and dynamically adjusting the index result according to a calibration coefficient corresponding to the type of the data acquisition equipment, and finally generating a standardized detection report. A xerophthalmia multi-index detection model is constructed based on an improved U-Net3 + architecture, a dry eye feature enhancement encoder and a cross-scale feature fusion decoder are adopted, a customized multi-task detection head is matched, an inter-task attention collaboration mechanism is established, meanwhile, a preprocessing algorithm and a dynamic calibration mechanism matched with a dry eye image are designed, and the detection accuracy of the xerophthalmia is improved. And multi-index synchronous, high-precision and high-efficiency detection is effectively realized.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Dry eye treatment apparatus and methods are described herein which generally comprise a patch or strip affixed to the skin of the upper and / or lower eyelids to deliver heat or other forms of energy, pressure, drugs, moisture, etc. (alone or in combination) to the one or more meibomian glands contained within the underlying skin. The treatment strip or strips include one or more strips configured to adhere to an underlying region of skin in proximity to one or both eyes of a subject such that the one or more strips allow for the subject to blink naturally without restriction from the one or more patches. Moreover, the one or more strips may be configured to emit energy to the underlying region of skin and where the one or more strips are shaped to follow a location of one or more meibomiam glands contained within the underlying region of skin.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

A dry eye treatment device, having a roller, a holder, wherein the roller contacts and rolls over an eyelid in a plurality of directions in a treatment; a heating element to generate heat, wherein at least a portion of the heat is transferred to the roller; a temperature monitoring system, which has a thermal sensor and a temperature control circuit; and an electric power source. The roller is of a convex cylindrical or concave cylindrical shape. A method for dry eye treatment, of cleaning an eyelid with a first cleansing wipe; heating a roller to a predetermined temperature; applying thermally conductive gel between the roller and the eyelid; rolling the roller over the eyelid in a plurality of directions; and removing the thermally conductive gel and expressed debris with a second cleansing wipe; and further, increasing the temperature by an increment and repeating the treatment method.

This invention relates to the use of recombinant type III humanized collagen and compositions comprising thereof in the ocular field. The invention provides the use of recombinant type III humanized collagen in the preparation of products for the prevention and / or treatment of ocular inflammation, and compositions comprising recombinant type III humanized collagen, and the use of these compositions in the preparation of products for the prevention and / or treatment of ocular inflammation and / or dry eye. Recombinant type III humanized collagen and compositions comprising thereof can significantly promote the renewal and repair of corneal epithelial cells, while inhibiting the release of inflammatory mediators, strengthening the ocular tissue barrier, enhancing tear film stability, and relieving ocular inflammation and dry eye.

The use of an opioid molecule, the levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3] dioxolo [4,5-glisoquinolin-5-yl]-3H-2-benzofuran-1-one, capable of CFTR modulation and of suppressing the degranulation of basophils and mast cells, for the treatment of dry eye and eyes suffering from allergies.

1. The name of the design product: dry eye near weak vision nursing instrument. 2. The use of the design product: for dry eye near weak vision nursing instrument. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

1. The name of this design product: Treatment head of meibomian gland treatment device. 2. Purpose of this design product: A treatment head for treating dry eyes. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture. 5. Other situations that require explanation Description of state changes: The treatment head has two states: expanded and closed. The expanded state is the non-treatment state, and the closed state is the treatment state.

The invention relates to a high-steam-quantity self-heating body and a steam eyeshade, the self-heating body comprises a nutrition layer and a heating layer, the nutrition layer is distributed on the inner side of the heating layer, and a temperature control breathable film I is arranged between the nutrition layer and the heating layer. The steam eyeshade has the advantages that the structure is simple, design is reasonable, the steam amount of the steam eyeshade can be obviously increased through the double-bag design, the physical thermal therapy effect is achieved, tear circulation and tear secretion are promoted, the nutritional condition of eye tissue is improved, and a certain effect is achieved for treating xerophthalmia.

The present application relates to the field of traditional Chinese medicine, in particular to a composition, eye patch and preparation method thereof for preventing and treating eye dryness, blurred vision fatigue and dry eye, comprising a carrier vehicle and a matrix layer, selecting medicinal materials with the effects of improving eyesight and resisting oxidation, fermenting the medicinal materials with plant lactic acid bacteria, bacillus or yeast to decompose macromolecules into small molecule active substances and possibly produce new active metabolites, adopting temperature control during the fermentation process to avoid high temperature from destroying heat-sensitive components, compounding the fermented medicinal material extract with hyaluronic acid, menthol, carboxymethyl cellulose and glycerol to form an intelligent rheological regulation body, hyaluronic acid synergistically enhances the moisturizing effect with the fermented extract, carboxymethyl cellulose serves as a film-forming agent to ensure the stability of the matrix layer, and glycerol improves the moisturizing performance, adopting a green process of activation, fermentation, mixing, loading and sterilization, selecting plant fibers as the carrier vehicle, cutting and packaging after loading the matrix layer, and then sterilizing to ensure the safety and effectiveness of the product.

The present invention relates to ophthalmic compositions comprising troxerutin and a surfactant selected from the group consisting of polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, and mixtures thereof, wherein the weight ratio of troxerutin to the surfactant is from 0.02:1 to 100:1, wherein the surfactant is present in an amount of up to 7 wt% with respect to the total weight of the composition, and wherein the composition is in the form of a solution, a suspension or a gel. The invention also relates to said composition for use in the treatment of dry eye disease.

This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same for the treatment of patients having moderate / severe or severe dry eye.

Methods to treat dry eye disease and to slow, inhibit or delay progression of dry eye disease in a subject are provided. The methods comprise administering a composition comprising a therapeutically effective amount of a compound that inhibits binding of an inflammatory interleukin-17 (IL-17) cytokine to an IL-17 receptor. In embodiments, the compounds is a protein or a peptide.

The present application relates to a dry eye treatment system. Dry eye treatment devices and methods are described herein, which generally include a patch or strip that is affixed to the skin of the upper and / or lower eyelid to deliver heat or other forms of energy, pressure, medication, moisture, etc. (alone or in combination) to one or more meibomian glands contained within the underlying skin. The treatment strip includes one or more strips configured to be attached to an area of skin beneath one or both eyes of a subject adjacent to the subject, such that the one or more strips allow the subject to blink naturally without being constrained by the one or more patches. In addition, the one or more strips can be configured to emit energy to the underlying skin area and wherein the one or more strips are shaped to conform to the position of one or more meibomian glands contained within the underlying skin area.

The invention relates to a product suitable for the treatment of tear film deficiency in dry eye disease and a method for manufacturing the product. The invention also relates to a product for use in the treatment of tear film deficiency in dry eye disease. The product according to the invention provides for an improved wound healing in dry eye disease and other pathologies.

The present application provides compositions and methods for treatment of ocular inflammatory conditions, dry eye diseases, and abnormal corneal neovascularization, using etiprednol. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, propylene glycol diacetate (PGD), a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, phenethyl alcohol, ethanol, isopropanol, glycerol, propylene glycol, polyethylene glycol, n-butanol, or combinations thereof. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of ocular inflammatory conditions, dry eye diseases, or abnormal corneal neovascularization.

The invention belongs to the technical field of biomedicine, and relates to a novel application of 3-O-methyl chrysotoxin, in particular to an application of 3-O-methyl chrysotoxin in preparation of a medicine for treating xerophthalmia. The core of the 3-O-methyl chrysotoxin disclosed by the invention is that the 3-O-methyl chrysotoxin effectively relieves corneal epithelial cell injury induced by hyperosmosis and inhibits oxidative stress and proinflammatory factor release by activating an EGFR (Epidermal Growth Factor Receptor) signal channel. In-vitro and in-vivo experiments prove that the composition can remarkably enhance cell activity, reduce apoptosis and active oxygen accumulation and repair the steady state of a tear film. The compound is applied to preparation of xerophthalmia drugs and has important clinical value.

The present disclosure provides a novel polypeptide. Also provided is an ophthalmic composition for treating or preventing dry eye (DE) or DE associated disorders. Also provided is a method for treating or preventing DE or DE associated disorders, stimulating tears, stabilizing tear film or any combination thereof in a subject in need thereof, comprising administering to the subject an effective amount of the novel peptides. Also provided is a contact lenses care product comprising the novel peptides and the preparation method thereof.